Table of Content

Introduction
Executive Summary
Fibroblast Growth Factor 2 (FGFR2): Overview
• FGFR2 Receptor - Overview
• Structure and Signaling of the FGFR2 Receptor
• Regulation of Synthesis and Release of FGFR2
• FGFR2 Metabolism
• FGFR2 Receptor Antagonists
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Fibroblast Growth Factor 2 (FGFR2)
In-depth Commercial Assessment
• Fibroblast Growth Factor 2 (FGFR2) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Fibroblast Growth Factor 2 (FGFR2) Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
• Comparative Analysis
RBM-007: Ribomic
• Product Description
• Research and Development
• Product Development Activities
ABSK 091: AstraZeneca
• Product Description
• Research and Development
• Product Development Activities
Early Stage Products (Phase I)
• Comparative Analysis
LY 2874455: Eli Lilly and Company
• Product Description
• Research and Development
• Product Development Activities
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Research programme: fibroblast growth factor receptor antagonists: Celon Pharma
• Product Description
• Research and Development
• Product Development Activities
Inactive Products
Comparative Analysis
• Fibroblast Growth Factor 2 (FGFR2) Key Companies
• Fibroblast Growth Factor 2 (FGFR2) Key Products
• Fibroblast Growth Factor 2 (FGFR2)- Unmet Needs
Fibroblast Growth Factor 2 (FGFR2)- Market Drivers and Barriers
• Fibroblast Growth Factor 2 (FGFR2)- Future Perspectives and Conclusion
• Fibroblast Growth Factor 2 (FGFR2) Analyst Views
• Fibroblast Growth Factor 2 (FGFR2) Key Companies
Appendix



List of Figures


Figure 1 Total Products for Fibroblast Growth Factor 2 (FGFR2)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

 

List of Tables


Table 1 Total Products for Fibroblast Growth Factor 2 (FGFR2)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products